Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
June 2017 Share this issue Facebook LinkedIn Twitter
 
I Welcome
Welcome to the June BNF eNewsletter.
Ten new drug monographs have been added to the BNF in the last month, including - amsacrine, ataluren, camellia sinensis, daratumumab, idebenone, ixazomib and palbociclib. We have included dose changes for medroxyprogesterone acetate: hot flushes caused by long-term androgen suppression in men with prostate cancer [unlicensed use].

This issue highlights new guidance on motor neurone disease as well as updated guidance on cholestasis, Crohn's disease, gallstones, inborn errors of bile acid synthesis, nocturnal enuresis in children, primary biliary cholangitis, Smith-Lemli-Opitz syndrome, ulcerative colitis and, urinary retention. We have also updated MHRA advice on risk of diabetic ketoacidosis with sodium-glucose co-transporter 2 inhibitors, risk of vascular occlusive events and advice on possible dose reduction with ponatinib and, signal of rebound effect after stopping or switching therapy with fingolimod. You will also find NICE technology appraisals for pegylated liposomal irinotecan.
Kind regards,
BNF Team
I In this issue
Significant changes More >  
News More >  
How to purchase BNF More >  
Price reminder More >  
Drug safety update More >  
Feedback More >  
I Significant
changes
This month's changes to the clinical content of these publications are described in two parts:

BNF and BNFC update should be read by all users
BNF update should be read by all users of the BNF
BNF 73 - BNFC 2016-2017
BNF Update
Amsacrine: new drug monograph
For further information, see amsacrine.
Palbociclib: new drug monograph
For further information, see palbociclib.
Safinamide: new drug monograph
For further information, see safinamide.
Reslizumab: new drug monograph
For further information, see reslizumab.
Ponatinib: risk of vascular occlusive events-updated advice on possible dose reduction (MHRA/CHM advice)
For further information, see ponatinib.
Fingolimod: signal of rebound effect after stopping or switching therapy (MHRA/CHM advice)
For further information, see fingolimod.
Dose changes
Medroxyprogesterone acetate: hot flushes caused by long-term androgen suppression in men with prostate cancer [unlicensed use]
For further information, see medroxyprogesterone acetate.
NICE technology appraisal update:
NICE technology appraisals that have been added to the BNF this month include:
Irinotecan hydrochloride: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine.
Other changes
To review other changes in the BNF, click on changes.
BNF for Children Update
Crohn's disease: updated guidance on management
For further information, see Crohn's disease.
Ulcerative colitis: updated guidance on management
For further information, see ulcerative colitis.
Smith-Lemli-Opitz syndrome: updated guidance on management
For further information, see Smith-Lemli-Opitz syndrome.
Other changes
To review other changes in BNF for Children, click on changes.
BNF BNF for Children Update
Ataluren: new drug monograph
For further information, see ataluren.
Idebenone: new drug monograph
For further information, see idebenone.
Urinary retention: updated guidance on management
For further information, see urinary retention.
Nocturnal enuresis in children: updated guidance on management
For further information, see nocturnal enuresis in children.
Cholestasis: updated guidance on management
For further information, see cholestasis.
Inborn errors of primary bile acid synthesis: updated guidance on management
For further information, see inborn errors of primary bile acid synthesis.
Primary biliary cholangitis: updated guidance on management
For further information, see primary biliary cholangitis.
I News
Reminder - help from CPPE with BNF 73
An interactive PDF e-learning programme from the Centre for Pharmacy Postgraduate Education (CPPE) will help you familiarise yourself with recommendations in BNF 73. It comprises 10 practical case studies, and can be accessed here.
BNF 73
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the March 2017 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
BNF is also available as a PDF eBook.
More
I Monthly price update reminder
Prices of all branded medicinal products in the BNF and BNFC are now updated monthly. Prices of generic preparations of medicinal products are updated every 2-4 months, to coincide with print editions of BNF and BNF for Children. The BNF team keep price information up to date using data sourced from the NHS dictionary of medicines and devices (dm+d).
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I Feedback on our eNewsletter
Please let us know if there are any issues that you'd like us to address in our eNewsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2017 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2017 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.